Nexalin Technology (NASDAQ:NXL) Upgraded at Maxim Group

Maxim Group upgraded shares of Nexalin Technology (NASDAQ:NXL) from a hold rating to a buy rating in a report published on Monday morning, Marketbeat.com reports. They currently have $5.00 target price on the stock.

Nexalin Technology Stock Performance

Shares of Nexalin Technology stock opened at $2.09 on Monday. Nexalin Technology has a one year low of $0.53 and a one year high of $4.49. The company has a market capitalization of $27.81 million, a PE ratio of -3.27 and a beta of 4.33. The company has a 50-day simple moving average of $2.76 and a two-hundred day simple moving average of $2.56.

Nexalin Technology (NASDAQ:NXL) last posted its earnings results on Friday, March 14th. The company reported ($0.28) EPS for the quarter. Nexalin Technology had a negative net margin of 3,407.98% and a negative return on equity of 187.59%. The firm had revenue of $0.03 million for the quarter.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Drive Wealth Management LLC acquired a new position in shares of Nexalin Technology during the 4th quarter worth approximately $55,000. Kingsview Wealth Management LLC purchased a new position in Nexalin Technology in the 4th quarter valued at about $28,000. Geode Capital Management LLC lifted its stake in Nexalin Technology by 36.3% in the 4th quarter. Geode Capital Management LLC now owns 107,241 shares of the company’s stock valued at $296,000 after buying an additional 28,544 shares in the last quarter. XTX Topco Ltd acquired a new stake in Nexalin Technology in the 4th quarter worth about $46,000. Finally, Northern Trust Corp purchased a new stake in Nexalin Technology during the 4th quarter worth approximately $36,000. Hedge funds and other institutional investors own 0.65% of the company’s stock.

Nexalin Technology Company Profile

Nexalin Technology, Inc, a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia.